Xu Q - Search Results

1

Copy number variations mediate major pathological response to induction chemo-immunotherapy in unresectable stage IIIA-IIIB lung cancer.

Zeng L, Zhou Y, Zhang X, Xu Q, Zhou C, Zeng F, Jiang W, Wang Z, Deng L, Yang H, Liu L, Xiong Y, Zhang B, Yang N, Zhang Y. Zeng L, et al. Among authors: xu q. Lung Cancer. 2023 Apr;178:134-142. doi: 10.1016/j.lungcan.2023.02.017. Epub 2023 Feb 24. Lung Cancer. 2023. PMID: 36858002

2

Comparison of Next-Generation Sequencing and Ventana Immunohistochemistry in Detecting ALK Rearrangements and Predicting the Efficacy of First-Line Crizotinib in Patients with Advanced Non-Small Cell Lung Cancer.

Zeng L, Li Y, Xu Q, Jiang W, Lizaso A, Mao X, Zhang Y, Yang N, Wang Z. Zeng L, et al. Among authors: xu q. Onco Targets Ther. 2020 Jul 22;13:7101-7109. doi: 10.2147/OTT.S265974. eCollection 2020. Onco Targets Ther. 2020. PMID: 32801744 Free PMC article.

3

Characterization of MET exon 14 alteration and association with clinical outcomes of crizotinib in Chinese lung cancers.

Yang H, Zhou Z, Lin L, Yang M, Li C, Li Z, Yu X, Lizaso A, Han-Zhang H, Li B, Xiang J, Mao X, Xu Q, Zhang Y, Yang N. Yang H, et al. Among authors: xu q. Lung Cancer. 2020 Oct;148:113-121. doi: 10.1016/j.lungcan.2020.08.009. Epub 2020 Aug 19. Lung Cancer. 2020. PMID: 32889305

4

A reply to "ROS1-mutant cancer and immune checkpoint inhibitors: A large database analysis".

Liu L, Xu Q, Lizaso A, Zhang Y. Liu L, et al. Among authors: xu q. Lung Cancer. 2020 Dec;150:254-255. doi: 10.1016/j.lungcan.2020.10.011. Epub 2020 Nov 1. Lung Cancer. 2020. PMID: 33153800 No abstract available.

5

Clinical impact of uncommon epidermal growth factor receptor exon 19 insertion-deletion variants on epidermal growth factor receptor-tyrosine kinase inhibitor efficacy in non-small-cell lung cancer.

Peng X, Long X, Liu L, Zeng L, Yang H, Jiang W, Liao D, Li K, Wang J, Lizaso A, Mao X, Xu Q, Mansfield AS, Yang N, Zhang Y. Peng X, et al. Among authors: xu q. Eur J Cancer. 2020 Dec;141:199-208. doi: 10.1016/j.ejca.2020.10.005. Epub 2020 Nov 7. Eur J Cancer. 2020. PMID: 33171317

6

A reply to "MET-mutant cancer and immune checkpoint inhibitors: A large database analysis".

Mi J, Xu Q, Lizaso A, Zhang Y. Mi J, et al. Among authors: xu q. Lung Cancer. 2020 Dec;150:259-260. doi: 10.1016/j.lungcan.2020.11.001. Epub 2020 Nov 5. Lung Cancer. 2020. PMID: 33187736 No abstract available.

7

Third left pulmonary lobe.

Zeng L, Xu Q, Yang N, Lizaso A, Zhang Y. Zeng L, et al. Among authors: xu q. Thorax. 2021 May;76(5):525. doi: 10.1136/thoraxjnl-2020-216130. Epub 2020 Nov 23. Thorax. 2021. PMID: 33229403 No abstract available.

8

Anlotinib combined with PD-1 blockade for the treatment of lung cancer: a real-world retrospective study in China.

Zhang X, Zeng L, Li Y, Xu Q, Yang H, Lizaso A, Mao X, Jin R, Zeng Y, Li Q, Wang J, Li Y, Zhang Y, Yang N. Zhang X, et al. Among authors: xu q. Cancer Immunol Immunother. 2021 Sep;70(9):2517-2528. doi: 10.1007/s00262-021-02869-9. Epub 2021 Feb 10. Cancer Immunol Immunother. 2021. PMID: 33566148 Free PMC article.

9

Brigatinib After Progression From Alectinib or Crizotinib: Paving the Way for Treatment Sequencing of ALK Inhibitors in ALK-Positive NSCLC.

Song L, Xu Q, Lizaso A, Zhang Y. Song L, et al. Among authors: xu q. J Thorac Oncol. 2021 Mar;16(3):349-351. doi: 10.1016/j.jtho.2020.11.023. J Thorac Oncol. 2021. PMID: 33641716 Free article. No abstract available.

10

Lung adenocarcinoma presents with diffuse bone metastasis.

Mi J, Xu Q, Zhang Y. Mi J, et al. Among authors: xu q. Thorac Cancer. 2021 Oct;12(19):2628-2629. doi: 10.1111/1759-7714.14110. Epub 2021 Aug 22. Thorac Cancer. 2021. PMID: 34423569 Free PMC article. No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

18,823 results

Search Page